Lv41
600 积分 2024-09-24 加入
BCMA CAR-T Therapy Is Safe and Effective for Refractory/Relapsed Multiple Myeloma With Central Nervous System Involvement
12天前
已完结
EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical endpoint for multiple myeloma
17天前
已完结
Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma
17天前
已完结
Demonstration of an ocular shell to the location of foreign radiopaque bodies
23天前
已关闭
Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial
1个月前
已完结
Novel strategies to manage CAR-T cell toxicity
1个月前
已完结
Genetic factors pertaining to the etiology of cerebral palsy
1个月前
已关闭
BCMA CAR-T Therapy Is Safe and Effective for Refractory/Relapsed Multiple Myeloma With Central Nervous System Involvement
1个月前
已完结
Recent Bendamustine Treatment before Apheresis Has a Negative Impact on Outcomes in Patients with Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy
2个月前
已完结
Recent Bendamustine Treatment before Apheresis Has a Negative Impact on Outcomes in Patients with Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy
2个月前
已关闭
皖公网安备34019202002308
